banner Click here for the Department of Dermatology Home Page Click here for the UC Irvine Home Page Click here for the School of Medicine Home Page
 
 
 
 

CLINICAL TRIALS

The UC Irvine Health Department of Dermatology conducts clinical research studies in therapeutic areas including psoriasis, acne, acne scars, eczema, atopic dermatitis, rosacea, skin cancer, actinic keratosis, hair and nail disorders, fungal disease, hemangioma, port-wine stain, cellulite, skin aging and photoaging, among others. Our researchers also have conducted various light technology trials using the pulsed dye laser, photodynamic therapy, fractionated CO2 laser, and the 1064 nm Nd:YAG laser. For over 25 years, we have been conducting clinical trials with a variety of well-renowned sponsors.

Active/Open to Enrollment

A Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata »

Alopecia areata (AA) is a chronic inflammatory disease characterized by non-scarring immune-mediated hair loss. AA typically presents as patches of hair loss in the scalp, but can progress to hair loss involving the entire scalp (alopecia areata totalis), or the entire body (alopecia areata universalis). Although AA is often considered a benign condition, it can cause significant emotional and psychosocial distress, especially in younger populations. There are currently no FDA approved treatments for AA and treatment regimens for patients with moderate to severe disease are often unsatisfactory.

 

This is a randomized control trial that aims to test a new investigational oral medication called CTP-543 in patients with moderate to severe AA. The study will take place over the course of 28 weeks. During that time those enrolled will take either the active study medication or a placebo twice a day and report to the research center on UCI main campus for regular physical exams, blood tests, and distribution of the medication. Participants must be between the ages of 18 and 65 years, must not be pregnant, or taking any immunosuppressive medications. The information collected from this study will be used to better understand the effects of CTP-543 on patients with AA and help researchers continue to develop new therapies in the future.

 

Study title: A Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata

Research Qualifications

Learn more about participation in clinical trials.